Some of the highlights from the September issue include:
- The 10th International Brain Tumour Awareness Week is nearly here: Saturday, 22nd October to Saturday, 29th October inclusive. No matter where you live, we'd be delighted if you would organise an awareness-raising activity and take part in this opportunity to increase awareness about brain tumours. For more information on how to get involved, and how to take part in the “World Walk”, please click here.
- Professor Ben Williams - a 21-year glioblastoma survivor - has published a free update to his book: “Surviving Terminal Cancer”. Originally published in 2002, he offers free updates that include the latest research and treatment developments. Download it or read online here.
- A study has found that delaying post-operative radiotherapy is linked to a worse outcome in children under 3 years of age with medulloblastoma. Concerns over the long-term effects of children in this age group have led to more patients deferring radiotherapy treatment, report the study's authors.
- Childhood cancer deaths are now the leading cause of cancer related deaths in the United States. From 1999 to 2014, deaths due to leukaemia have fallen while brain tumours deaths has remained largely unchanged: “Pediatric brain tumors have not become deadlier over the years – survival rates for these patients have stayed relatively flat for decades,” said David F. Arons, chief executive of the National Brain Tumor Society, who prepared the report.
- Novocure has announced that long-term data from a trial of newly diagnosed glioblastoma patients using Optune (a portable Tumor Treating Fields device) in combination with temozolomide shows improved survival rates at four years, with extended progression-free survival. Results are to be presented at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) in Scottsdale, Arizona, on 18 November, 2016..
- Results from a phase II trial of the chemotherapy drug vinblastine in progressive low grade glioma patients aged under 18 has shown it to be as effective as other current therapies, and was reported to not affect quality of life.
- Non-small cell lung cancer patients who have brain metastases do not benefit from whole brain radiotherapy as it has little or no effect on overall survival, according to trial results from published in The Lancet.
- You can read the IBTA e-News September edition in full online here. You can sign up to receive the e-News every month by registering here.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences.
To see an archive of existing e-News issues, click here.